Today: 8 June 2026
Browse Category

Biotechnology 18 October 2025 - 28 October 2025

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Therapeutics shares plunged nearly 45% on Oct. 27 after the company halted two Phase 3 trials of its CRISPR therapy due to a patient suffering severe liver toxicity. The stock dropped from the mid-$20s to the low-teens, with NTLA trading around $14–15 as of midday Oct. 28. Several analysts downgraded the stock and cut price targets following the safety incident.
28 October 2025
···
Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics shares jumped over 200% to close at $1.07 on October 27 after announcing a joint venture with Arabian Eagle Manufacturing to distribute PCR tests across the Middle East and North Africa. Trading volume topped 100 million shares amid a surge in retail investor activity. The company recently reported Q2 revenue of $200,000, down sharply from the prior year. Analyst price targets ranged from $1.00 to $3.00.
27 October 2025
··
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics shares plunged nearly 45% Monday after the company halted two Phase 3 trials of its CRISPR therapy NTLA-2001 due to a severe liver injury in a patient. The stock dropped from about $19 to the low teens, with CRISPR Therapeutics also falling 10%. Intellia paused dosing and enrollment following the Grade 4 liver event and is consulting regulators on next steps.
27 October 2025
···
CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics traded near $67 on Oct. 27, down 3% after safety concerns hit gene-editing stocks. Shares remain up nearly 100% in 2025, fueled by a major preclinical breakthrough and global rollout of its Casgevy therapy. Rival Intellia plunged 45% after a trial pause, dragging CRSP down 10% in sympathy. Analysts remain bullish, with targets up to $93 despite sector volatility.
27 October 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion Pharmaceuticals closed at $6.04 on Oct. 24, 2025, after volatile trading and a 44% monthly surge. Q2 revenue rose 33% to $19.2 million, but net loss reached $171.9 million as R&D spending climbed. The company completed a $630 million merger with Exscientia and reported $534 million cash on hand. Key drug candidates advanced in clinical trials, with several late-stage readouts expected by year-end.
26 October 2025
···
NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis announced FDA 510(k) clearance for its PENFS device to treat adult functional dyspepsia on Oct. 24, marking the first approved therapy for this condition. NRXS shares rose to $3.82 on Oct. 23 and traded higher pre-market after the news. The company recently raised $5 million and expanded insurance coverage to 53 million lives. Q2 revenue grew 46% year-over-year; analyst sentiment remains mixed.
24 October 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science shares surged over 300% in early trading Oct. 24 after announcing an expanded partnership with Anemocyte to develop off-the-shelf lentiviral vector plasmid DNA for cell therapies. The company’s lead candidate Temferon showed a 29% two-year survival rate in glioblastoma patients, more than double standard care. Net loss narrowed to €3.83M in H1 2025. Analyst targets average $22.73, far above current prices.
24 October 2025
··
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx’s ozekibart cut risk of progression or death by 52% in Phase 2 chondrosarcoma trial, doubling median progression-free survival to 5.52 months versus placebo. Shares of INBX jumped about 70% intraday and closed at $28.36 on Oct. 23, then surged another 75–80% after hours. Management plans a BLA filing in Q2 2026. Ozekibart also showed high response rates in colorectal and Ewing sarcoma cohorts.
24 October 2025
··
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics shares rose about 17% to $30 after the FDA granted RMAT and Orphan Drug designations to its lead gene-editing programs, BEAM-101 and BEAM-302. Early trial data showed BEAM-302 raised protective AAT levels and BEAM-101 produced durable increases in fetal hemoglobin. Wall Street’s average 12-month price target is $45–46, implying roughly 70–80% upside.
21 October 2025
··
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Spero shares closed at $2.29 on Oct. 20, 2025, up 3.6%, after reporting Phase 3 trial results showing oral tebipenem HBr matched IV imipenem in overall success (58.5% vs 60.2%) at IDWeek. The stock has surged over 120% year-to-date, trading between $0.51 and $3.22. GSK plans an FDA submission in Q4. Analyst 12-month targets average $5, but ratings remain mixed following a recent Zacks downgrade.
21 October 2025
···
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics shares jumped 17% to $30.35 on Oct. 20, 2025, marking their highest level since early 2024. The rally followed bullish technical signals and positive clinical updates for its gene-editing therapies. Analysts at Jefferies and H.C. Wainwright reiterated Buy ratings, with price targets up to $80. Beam ended Q2 with $1.2 billion in cash, enough to fund operations into 2028.
20 October 2025
·····
Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Celcuity shares jumped over 40% Monday to a record near $80 after Phase 3 trial data showed its drug gedatolisib cut risk of progression or death by 76% in advanced HR+/HER2- breast cancer. The company confirmed full enrollment of the PIK3CA-mutant cohort, with final results expected by mid-2026. Needham raised its price target to $95. Celcuity’s market cap topped $2.2 billion.
20 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL shares surged 14% to a record $85.35 on Oct. 16 after Samsung agreed to invest $110 million and partner on cancer test rollout in Asia. New trial data showed Galleri’s blood test boosted early cancer detection seven-fold in a 25,000-patient study. GRAIL secured $325 million in fresh funding, extending its cash runway into 2030. Analysts remain cautious, with a consensus Hold rating and a $57 price target.
20 October 2025
···
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences shares closed at $2.14 on Oct. 17, up about 100% year-to-date, then surged another 38% after hours. BlackRock disclosed a 5.4% stake on Oct. 18, joining other major funds that increased holdings in Q2. Sellas’s lead AML drug passed a Phase 3 interim safety review, and its CDK9 inhibitor showed promising Phase 2 results. The company ended Q2 with $25 million cash and raised $23.6 million in September.
20 October 2025
··
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics shares closed at $33.53 Friday, near recent highs after rebounding from a 40% drop in August. Its obesity drug VK2735 showed 12.2% weight loss in a Phase 2 trial but had a 20% dropout rate from side effects. Analysts see Viking as a possible acquisition target amid recent industry deals. The company holds over $800 million in cash and reports Q3 earnings on Oct. 22.
19 October 2025
··
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics shares traded near $69 in mid-October after rising about 40–45% over the past year. The company plans to raise up to $600 million in a new share offering announced October 15. Bank of America raised its price target to $93 and maintained a Buy rating. CRISPR reported preclinical success for CTX460 and continues to expand Casgevy’s commercial reach.
19 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL shares surged 13–14% to a record $85.35 on Oct. 16 after announcing a $110 million equity deal with Samsung and plans to bring its Galleri cancer test to Asia. New trial data at ESMO showed Galleri doubled early cancer detection versus routine screening. Despite gains, most analysts rate GRAL a “Hold” with an average target below current prices. Q2 revenue rose 11% to $35.5M; net loss narrowed to $114M.
18 October 2025
···
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
1 … 13 14 15 16 17 18

Stock Market Today

  • Morgan Stanley Initiates Cerebras Stock with Overweight Rating on AI Potential
    June 8, 2026, 2:07 AM EDT. Morgan Stanley has initiated coverage of Cerebras Systems with an overweight rating, citing significant growth opportunities in AI inference technology. The investment bank highlights Cerebras' advanced chip architecture designed to accelerate artificial intelligence workloads. This move reflects growing investor interest in hardware companies that support AI applications.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop